Leiomyosarcoma Clinical Trial
Official title:
Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
This is an open label single site Phase II clinical trial to identify a potentially
promising therapy dose for Sunitinib malate. The study drug will be taken orally once daily
on days 1 through 28 of each 42 day cycle. Treatment will be continued until there is either
disease progression or cumulative/acute toxicity.
All patients with unresectable or metastatic soft tissue sarcoma (STS): leiomyosarcoma,
liposarcoma, fibrosarcoma, and malignant fibrous histiocytoma (MFH) seen at the Moffitt
Cancer Center will be screened for eligibility to be enrolled in the study.
Status | Completed |
Enrollment | 48 |
Est. completion date | December 2011 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Resolution of all acute toxic effects of prior chemotherapy or radiotherapy or surgical procedures to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 grade less than or equal to 1. - Adequate organ function as defined by the following criteria: - Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) less than or equal to 2.5 x local laboratory upper limit of normal (ULN), or AST and ALT less than or equal to 5 x ULN if liver function abnormalities are due to underlying malignancy - Total serum bilirubin less than or equal to 1.5 x ULN - Absolute neutrophil count (ANC) greater than or equal to1500/microL - Platelets greater than or equal to 100,000/microL - Hemoglobin greater than or equal to 9.0 g/dL - Serum calcium less than or equal to 12.0 mg/dL - Serum creatinine less than or equal to 1.5 x ULN - Histologically-proven liposarcoma, leiomyosarcoma, fibrosarcoma, or MFH - Measurable disease radiographically - Disease that is deemed surgically unresectable and/or metastatic - Age greater than or equal to 18 years - Life expectancy greater than 16 weeks - Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2 - Patients may have had up to 3 prior chemotherapies within 4 weeks of starting the study treatment. Exclusion Criteria: - Major surgery or radiation therapy or chemotherapy within 4 weeks of starting the study treatment. - NCI CTCAE version 3 grade 3 hemorrhage within 4 weeks of starting the study treatment. - History of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or evidence of symptomatic brain or leptomeningeal disease. - Any of the following within the 6 months prior to study drug administration: - myocardial infarction, - severe/unstable angina, - coronary/peripheral artery bypass graft, - symptomatic congestive heart failure, - cerebrovascular accident or transient ischemic attack, or pulmonary embolism - Ongoing cardiac dysrhythmias of NCI CTCAE greater than or equal to grade 2 - Prolonged QTc interval on baseline electrocardiogram (ECG) > 500 msec. - Hypertension that cannot be controlled by medications (>150/100 mm Hg despite optimal medical therapy) - Prior tyrosine kinase inhibitor therapy - Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication - Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness or other active infection - Concurrent treatment on another clinical trial, except supportive care or non-treatment trials - Concomitant use of agents known to induce or inhibit CYP3A4 - Concomitant use of agents metabolized by the cytochrome P450 system - Ongoing treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg by mouth [PO] daily for thrombo-prophylaxis is allowed) - Pregnancy or breastfeeding patients - Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
H. Lee Moffitt Cancer Center and Research Institute | Pfizer |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Overall Response (OR) | Objective Radiographic Response Rate. Response assessments were based on the longest diameter tumor measurements in accordance with Response Evaluation Criteria in Solid Tumors (RECIST). | From On Treatment to Off Study - average of 6 months | No |
Secondary | Participants' Progression Free Survival (PFS) | Time to tumor progression defined as the duration of time from start of treatment to time of progression. Response assessments were based on the longest diameter tumor measurements in accordance with Response Evaluation Criteria in Solid Tumors (RECIST). | From On Treatment to Off Study - average of 6 months | No |
Secondary | Participants' Overall Survival (OS) | The median OS times (months) for liposarcoma, leiomyosarcoma and MFH. | From On Treatment to Off Study - average of 6 months | No |
Secondary | Number of Participants With Serious Adverse Events (SAEs) | Determine the number of participants who experience Serious Adverse events while on sunitinib malate study. | 4 years, 7 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04535271 -
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma
|
Phase 2 | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT06088290 -
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
Terminated |
NCT02940041 -
Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors
|
||
Completed |
NCT01442662 -
Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine
|
Phase 2 | |
Completed |
NCT00062868 -
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
|
Phase 1 | |
Recruiting |
NCT04214457 -
Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas
|
||
Active, not recruiting |
NCT04420975 -
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
|
Phase 1 | |
Terminated |
NCT04099277 -
A Study of LY3435151 in Participants With Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05548179 -
Exploring Clinical Trial Experiences of People With Leiomyosarcoma
|
||
Recruiting |
NCT02983539 -
Detection of Circulating Tumor Cells in Patients With Sarcomas
|
||
Completed |
NCT00093080 -
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
|
Phase 2 | |
Active, not recruiting |
NCT04624178 -
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
|
Phase 2 | |
Terminated |
NCT03959033 -
Patient Reported Outcome Measures (PROMs) With Trabectedin
|
||
Recruiting |
NCT02275286 -
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01956084 -
Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma
|
Phase 1 | |
Completed |
NCT01426633 -
Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
|
Phase 1 | |
Recruiting |
NCT05080790 -
Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma
|
Phase 2 | |
Active, not recruiting |
NCT05269355 -
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
|
Phase 2/Phase 3 |